SEACOR ® Ethyl esters of polyunsaturated fatty acids

SEACOR ® is a drug based on ethyl esters of polyunsaturated fatty acids (EPA and DHA not less than 85%).

THERAPEUTIC GROUP: Lipid-lowering agents - Ethyl esters of polyunsaturated fatty acids

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications SEACOR ®

SEACOR ® is indicated for the treatment of hypertriglyceridemia. The intake of this drug should follow or possibly be combined with a suitable diet plan.

SEACOR ® can also be used in the prevention of cardiovascular accidents in patients with a history of myocardial infarction.

SEACOR ® action mechanism

The oral intake of SEACOR ® guarantees a significant intake of ethyl esters of polyunsaturated fatty acids, which are effectively absorbed in the intestine. Like other lipids, since they cannot circulate freely in the circulatory stream, these nutrients are transported in the form of lipoproteins (in particular chylomicrons and VLDL).

The hypolipidemic therapeutic action is justified by the ability of eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) to reduce the hepatic synthesis of triglycerides and cholesterol, rebalancing the patient's lipidemic profile. Preventive action against cardiovascular diseases is instead determined by their antithrombotic, anti-inflammatory and anti-platelet aggregation activity.

These effects are mainly achieved through a competitive mechanism with respect to arachidonic acid, which allows the synthesis - by endothelial and leukocyte cells - of prostaglandins and leukotrienes with marked pro-inflammatory activity to be reduced.

To these effects are added others, such as the anti-arrhythmic and vasoprotective, which are still under study and characterization.

Studies carried out and clinical efficacy

OMEGA 3 AND DEFICIT OF ATTENTION AND HYPERACTIVITY

Several studies agree that an omega 3 deficiency could lead to a decrease in cognitive abilities through an increase in pro-inflammatory stimuli and hormonal deregulation.

This study, even without bringing statistically important evidence, shows how supplementation with PUFA for 3-4 months in children with attention deficit and hyperactivity, may favor a regression of symptoms. These results are in line with other studies that highlight the positive effects of omega 3 on the ability to concentrate in healthy individuals and also in athletes.

2. OMEGA 3 AND POST-INFECTION MORTALITY

Newly published study that evaluates the effectiveness of omega 3 in the therapeutic-preventive protocol of the post-infarcted patient. In contrast to therapeutic indications, this very important study did not observe a statistically significant reduction in mortality in infarcted patients treated for one year with omega 3.

3. THE OMEGA 3 AND THE DISORDERS OF THE MOOD

As is well known, omega 3 is part of the brain cellular structure, modulating its function. Several studies have shown that a deficiency of EPA and DHA can be associated with the genesis of depression. For this reason, in the literature there are numerous studies designed to evaluate the effectiveness of the integration with omega 3 in improving mood disorders. Although there are no clinical trials of particular importance that allow us to obtain a statistically valid data, the first evidence suggests an "antidepressant" role, probably associated with the reduction of inflammatory prostaglandins and the consequent increase in neurotrophic factors.

Method of use and dosage

SEACOR ® soft capsules of 500mg / 1000mg of ethyl esters of polyunsaturated fatty acids, titrated to EPA and DHA at least 85% and with a ratio 0.9 / 1.5: in the treatment of hypertriglyceridemia the recommended dosage is 3 soft capsules of 1 gram per day, divided into 3 different assumptions. Pharmacological treatment should be started only in case of failure of previous non-pharmacological lipid-lowering strategies (adequate lifestyle and hypolipid diet). Any dosage corrections should be made by the doctor following a careful assessment of the patient's state of health and therapeutic goals.

In the primary prevention of the infarcted subject the daily dosage of 1 gram is preferred.

IN ANY CASE, BEFORE TAKING SEACOR ® - THE REQUIREMENT AND CHECK OF YOUR DOCTOR IS NECESSARY.

Warnings SEACOR ®

SEACOR ® more generally the ethyl esters of polyunsaturated fatty acids, is very well tolerated and has no special precautions for use. However, like any other lipid-lowering drug therapy, it is advisable to follow a hypolipidic diet and healthy lifestyle before and during the intake.

The administration of this drug in patients suffering from haemorrhagic diseases or subjected to anticoagulant therapy should be carefully supervised by a doctor in order to avoid the onset of bleeding episodes.

PREGNANCY AND BREASTFEEDING

Although there is no specific evidence and clinical trials in this regard, the intake of omega 3 does not seem to present mutagenic and teratogenic effects on the fetus. Despite this, it would always be advisable to consult your doctor and your gynecologist in order to assess the correct relationship between risks and benefits.

Interactions

The high safety profile of polyunsaturated fatty acids, which we remember to be present normally in nature, minimizes the risk of drug and non-drug interactions, potentially dangerous for the patient's health. In fact, the only drugs that - taken simultaneously with SEACOR ® could compromise the patient's state of health, are the anticoagulants, which in particular could favor the presence of bleeding phenomena.